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Abstract.
Background: Neuropsychological testing has long been embedded in daily clinical practice at memory clinics but the added
value of a complete neuropsychological assessment (NPA) to standard clinical evaluation is unknown.
Objective: To evaluate the added diagnostic and prognostic value of NPA to clinical evaluation only in memory clinic patients.
Methods: In 221 memory clinic patients of a prospective cohort study, clinical experts diagnosed clinical syndrome (subjective
cognitive impairment (SCI), mild cognitive impairment (MCI), or dementia) and etiology (Alzheimer’s disease (AD) or no
AD), and provided a prognosis of disease course (decline or no decline) before and after results of NPA were made available.
The reference standard was a panel consensus based on all clinical information at baseline and up to 2 follow-up assessments.
Results: With NPA data available, clinicians changed their initial syndromal diagnosis in 22% of patients, and the etiological
diagnosis as well as the prognosis in 15%. This led to an increase in correctly classified cases of 18% for syndromal diagnosis,
5% for etiological diagnosis, and 1% for prognosis. NPA data resulted in the largest improvement in patients initially classified
as SCI (syndrome: 93.3% (n = 14) correctly reclassified, etiology: net reclassification improvement [NRI] = 0.61, prognosis:
NRI = 0.13) or MCI (syndrome: 89.3% (n = 23) correctly reclassified, etiology: NRI = 0.17, prognosis: NRI = 0.14), while
there was no improvement in patients with dementia (syndrome: 100% (n = 1) correctly reclassified, etiology: NRI = –0.05,
prognosis: NRI = –0.06). Overall, inclusion of NPA in the diagnostic process increased confidence in all diagnoses with 6-7%.
∗Correspondence to: Willemijn J. Jansen, Department of Psy-
chiatry and Neuropsychology, Maastricht University, P.O. Box
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Conclusion: Administration of a complete NPA after standard clinical evaluation has added value for diagnosing cognitive
syndrome and its underlying etiology in patients regarded as non-demented based on the first clinical impression.
Keywords: Alzheimer’s disease, cognitive disorders, consensus, diagnosis, prognosis, mild cognitive impairment,
neuropsychological tests, outpatient clinic, reclassification
INTRODUCTION
A timely and accurate diagnosis in people with
cognitive complaints can answer concerns about
symptoms [1], facilitate adjustment [2], and is
essential to initiate appropriate care and treatment
[3]. However, differentiating between normal aging,
mild cognitive impairment (MCI), and dementia,
determining the underlying cause for cognitive com-
plaints, and making a reliable prognosis for a patient
is often challenging in clinical practice [4, 5].
The diagnostic assessment of patients presenting
at a memory clinic with a cognitive complaint starts
with clinical evaluation by a medical doctor and
may be followed by neuropsychological assessment
(NPA), depending on the setting. Many studies have
shown that several single neuropsychological tests,
isolated or combined, can predict future dementia [6]
and differentiate between Alzheimer’s disease (AD)
and other common causes for cognitive impairment
[7–10]. Neuropsychological testing has long been
embedded for both diagnostic and treatment purposes
in daily clinical practice at memory clinics and is
a useful additional test according to clinical criteria
for AD and neurocognitive disorders [11]. However,
the added diagnostic and prognostic value of a com-
plete NPA to the clinical evaluation has not been
systematically assessed. Identification of the optimal
diagnostic strategy in patients with cognitive com-
plaints is important to ensure an accurate diagnosis
and prognosis, without preventing valuable testing or
exposing patients to unnecessary testing.
We therefore aimed to evaluate the added diag-
nostic and prognostic value of NPA as administered
after the clinical evaluation in tertiary memory clinic
patients and to derive strategies for optimal use of
NPA as a diagnostic instrument. A staged clinical
decision-making process was used to compare the
usefulness of the standard clinical evaluation with-
out and with NPA to diagnose cognitive syndrome,
differentiate between AD and other etiologies, and
to make a disease course prognosis. We examined
change in diagnostic accuracy, correct reclassifica-
tion, net reclassification improvement and change in
diagnostic confidence related to NPA when added to
the standard clinical evaluation.
MATERIALS AND METHODS
Participants
We selected participants from the prospective
Leiden-Alzheimer Research Netherlands (LeARN)
study [12]. In this study, consecutive patients from
four Dutch academic memory clinics (Maastricht
University Medical Center, VU Medical Center, Rad-
boud University Medical Center, Leiden University
Medical Center) were included between 2009 and
2011 and annually followed for two years. Inclusion
criteria were referral for a cognitive complaint by a
physician or suspicion of a cognitive disorder, a Mini-
Mental State Examination (MMSE [13]) score ≥ 20
[14], and a Clinical Dementia Rating (CDR [15])
score ≤ 1. Patients were excluded if the cognitive
problems were due to stroke, neurological disorder,
major psychiatric disorder, or substance abuse, or
when a reliable informant was absent. The Medi-
cal Ethics Committee of each participating center
approved this study and all patients initially included
and their informal caregivers gave written informed
consent.
Of the 304 participants who met inclusion crite-
ria for the LeARN study, 221 patients were included
in the current analyses. Eligibility for these analy-
ses required availability of at least one follow-up
assessment at one or two years after the baseline
assessment. Patients who died (n = 3), were insti-
tutionalized (n = 4), unwilling to further participate
(n = 62), or could not be reached (n = 14) were there-
fore excluded. Of these, 163 (74%) had both a 1-year
and a 2-year follow-up assessment, 39 (18%) had only
a 1-year and 19 (9%) had only a 2-year follow-up
assessment. Eligible patients and excluded patients
did not differ in age at baseline, years of education,
MMSE score, CDR score, or clinical diagnosis at
baseline.
Clinical evaluation
At baseline and follow-up, participants under-
went a standardized clinical evaluation consisting
of a detailed history provided by the patient and
informant, a psychiatric, neurological, and physical
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examination, and assessment using clinical rating
scales. Clinical rating scales included the MMSE
[13], the CDR [15], the Geriatric Depression Scale-15
(GDS-15) [16], the Neuropsychiatric Inventory (NPI)
[17], and the Disability Assessment for Dementia
(DAD) [18].
Neuropsychological assessment
Neuropsychological assessment was administered
at baseline and repeated annually, and consisted of
a standardized battery of Dutch versions of cogni-
tive tests [19]. Tests included the Auditory Verbal
Learning Test (AVLT) [20] comprising an immedi-
ate recall of 5 trials of 15 semantically unrelated
words and a delayed recall and recognition after
20 minutes to assess verbal memory, the Visual
Association Test (VAT) [21] to assess visual mem-
ory, the Digit Span task of the WAIS III (forward
and backward) [22] to evaluate working memory,
a one-minute verbal fluency test using a semantic
category cue (animals) [23] to assess language func-
tion, the Letter Digit Substitution Test (LDST) [24]
to assess information processing speed, the Stroop
Color-Word Test (SCWT) [25] and the Trail Mak-
ing Test (TMT) (Part A ‘letters’ and Part B ‘concept
shifting’) [26] to assess attention and executive func-
tioning, and subtests of the Visual and Object Spatial
Perception (VOSP) test [27] to assess visual per-
ception. Raw test scores were converted to z-scores
using Dutch norms adjusting for age, gender, and
education.
Neuroimaging
Neuroimaging by magnetic resonance imaging
(MRI) took place at baseline only. Measures of
medial temporal lobe atrophy (MTA), scored with
the MTA scale [28], white matter lesions scored with
the Fazekas scale [29], and the number of infarcts,
lacunes and microbleeds were derived from the 3T
MRI images, which were acquired following the stan-
dardized Parelsnoer protocol [19].
Diagnostic procedure
All patient information was summarized in dig-
ital case descriptions and presented to individual
members of an expert panel in a stepwise fashion
to simulate clinical practice (Fig. 1), as previously
described [30]. An expert panel was composed of
clinicians from three different disciplines (geriatrics,
geriatric psychiatry, and neurology) with at least five
years of clinical experience in a memory clinic. This
included experience with integrating neuropsycho-
logical test information in their diagnostic reasoning.
At each stage, experts were asked to individually
diagnose the patients’ syndrome and etiology under-
lying the cognitive complaints, and to predict the
course of cognitive symptoms and daily function-
ing in the next two years. The syndrome could be
classified as: subjective cognitive impairment (SCI),
MCI, or dementia; the etiology as: AD, vascular,
frontotemporal, Lewy Body or Parkinson’s, other,
or no neurodegenerative disease; and the disease
course prognosis as: improvement, stable, or decline.
Experts also indicated confidence in their diagno-
sis on a scale from 0% (very uncertain) to 100%
(fully convinced) at each stage. Firstly, the infor-
mation from the clinical evaluation as described
above was presented to the individual experts result-
ing in the initial clinic only diagnosis on syndrome,
etiology and predicted disease course. Secondly, neu-
ropsychological test results (z-scores) and a short
summary of the neuropsychologist were presented
as add-on to the clinical information and interpreted
by the experts to make a subsequent clinic + NPA
diagnosis. The short summary provided by the neu-
ropsychologist consisted of 2-3 sentences in which
performance on all individual cognitive domains
tested was objectively described as “(very) high”,
“above average”, “average”, “below average”, or
“(very) low” without including an opinion or diag-
nosis. Characteristic observations conducted during
testing were also included. Thirdly, the baseline infor-
mation on the clinical evaluation and NPA results
combined with measures from the MRI scan was pre-
sented and integrated by the experts in the baseline
diagnosis. Lastly, all information from baseline and
follow-up was presented to determine the follow-up
diagnosis.
The same trio of experts completed all steps for
each case. Experts did not take notes during any of
the assessments. Experts were not obliged to apply
strict decision rules but were recommended to use
diagnostic guidelines as they would do in clinical
practice. The patient’s name was de-identified and
the number of cases in which the expert and the
participant originated from the same clinical center
was minimized to prevent experts from recognizing
a case. However, this could not be fully prevented,
which resulted in the recognition of one case by one
expert.
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Fig. 1. The staged diagnostic procedure followed for each patient. NPA, neuropsychological assessment; MRI, magnetic resonance imaging.
Consensus procedure
For the clinic only and clinic + NPA diagnoses for
each patient, we adopted the syndrome (SCI, MCI,
or dementia), etiology (dichotomized into AD or no
AD) and prognosis (dichotomized into decline or no
decline) as designated by the majority of experts (at
least 2 out of 3).
For the baseline diagnoses, consensus among
members of an expert panel on the syndrome was
determined and for the follow-up diagnoses, consen-
sus on the etiology and predicted disease course was
determined. In case of discrepancy, a meeting was
organized approximately 2 weeks after the initial rat-
ing in which the expert trios were invited to express
their arguments and reach consensus. This procedure
resulted in the consensus syndrome, consensus eti-
ology (dichotomized), and consensus disease course
(dichotomized) that were used as reference standards
for syndrome, etiology and disease course prognosis.
Data analysis
Syndrome, etiology and prognosis for the clinic
only and clinic + NPA diagnoses were compared
against their reference standards. Percentages cor-
rectly classified in the clinic only and clinic + NPA
diagnoses were calculated for syndrome, etiology
and predicted disease course and compared with the
McNemar test statistic for paired proportions. We cal-
culated sensitivity and specificity, positive predictive
value and negative predictive value for the etiology
and disease course classifications of the clinic only
and clinic + NPA diagnoses. Mean certainty of the
clinic only and clinic + NPA diagnoses and prog-
noses was compared with paired-sample t-tests. The
added value of NPA was expressed in percentages
of (correct) reclassifications in syndrome, etiology
and predicted disease course from clinic only and
clinic + NPA diagnosis determined using reclassifi-
cation tables. Category-based Net Reclassification
Indices (NRI) for events (AD or decline) and non-
events (no AD or no decline) were calculated for the
etiology and predicted disease course classifications.
The NRI is the difference in proportions reclassi-
fied upwards and downwards among events versus
non-events, or NRI = [Pr(up | events) – Pr(down |
events)] + [Pr(down | non-events) – Pr(up | non-
events)] = NRI events + NRI non-events [31]. NRI
events and NRI non-events represent the net per-
centage of patients with or without events correctly
assigned after receiving the NPA results. Z-scores for
the NRIs were calculated according to the method
of Pencina et al. [31] and compared with the stan-
dard normal distribution. To identify in which cases
the NPA had added value, clinical characteristics and
NPA results of patients in whom syndrome, etiol-
ogy, or course was correctly reclassified from clinic
only to clinic + NPA diagnosis were compared with
those of patients in whom there was no or incor-
rect reclassification using independent t-tests and
chi-square tests. Percentages of correct and incorrect
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reclassification were calculated for each value of the
predictor. We also characterized patients in whom eti-
ology or course was correctly not reclassified from
clinic only to clinic + NPA diagnosis to identify in
which cases the NPA had no added value. Analyses
were conducted with SPSS version 20.0 (Chicago,
IL, USA) and significance level was set at p < 0.05.
RESULTS
Baseline characteristics of the sample are dis-
played in Table 1. Of the 221 patients included in
the analyses, 52 were diagnosed with SCI, 90 with
MCI, and 79 with dementia at consensus syndrome.
Based on the consensus etiology, cognitive problems
were caused by AD in 102 (46%) patients (2 SCI,
43 MCI, 57 dementia). Clinically relevant cognitive
or functional decline over the follow-up period was
observed in 128 (58%) participants (5 SCI, 53 MCI,
70 dementia) based on the consensus disease course.
The experts did not reach consensus on the reference
etiology in 1 case, and on the reference disease course
in 3 cases. In these participants a majority decision
was adopted.
Comparison of clinic only and clinic + NPA
diagnoses
In these analyses, we directly compared the
syndrome, etiology, and predicted disease course
assigned to patients in the clinic only and in the
clinic + NPA diagnoses with the reference standards
to examine correct classification. The syndrome
was initially correctly classified in 70.7% (n = 152,
indeterminate diagnosis in 6 cases) of patients, which
increased to 88.5% (n = 192, indeterminate diagno-
sis in 4 cases) after NPA results were disclosed
(χ2 = 15.2, p < 0.001). The mean certainty of the
experts in their syndrome classification increased
from 68.0% to 74.3% (t = –10.9, p < 0.001) after
making NPA data available. Diagnostic accuracy
measures of the etiology and predicted disease
course classifications are displayed in Table 2. Cor-
rect classifications of etiology in 76.5% of patients
by the clinic only diagnosis increased to 81.0%
by the clinic + NPA diagnosis (χ2 = 10.0, p = 0.002).
In making a disease course prognosis, the per-
centage correctly classified cases slightly increased
after presentation of NPA results from 74.7% to
75.6% (χ2 = 0.5, p = 0.48). The experts were 6-7%
more certain of both etiology (t = –12.1, p < 0.001)
and predicted disease course (t = –10.1, p < 0.001)
classifications after reviewing the NPA. Supplemen-
tary Table 2 presents measures of classification
separately for patients with up to 2 years of
follow-up and patients with only a 1-year follow-up
assessment.
Reclassification of diagnoses
We also examined the reclassification of syndrome,
etiology, and predicted disease course from clinic
only diagnosis to clinic + NPA diagnosis and deter-
mined whether this reclassification was correct based
on the reference standards. Table 3 displays the
reclassification of syndromes assigned to patients at
the clinic only and clinic + NPA stages compared to
the consensus syndrome. Overall, the initial clas-
sification of syndrome changed in 20.7% (n = 44,
indeterminate diagnosis in 9 cases) after reviewing
NPA results, which were correct when compared to
Table 1
Baseline characteristics
Characteristics Consensus syndrome
All (n = 221) SCI (n = 52) MCI (n = 90) Dementia (n = 79)
Age, years 66.6 ± 9.3 62.9 ± 9.0 67.4 ± 8.7) 68.0 ± 9.7
Female, n (%) 78 (35.3) 20 (38.5) 30 (33.3) 28 (35.4)
Education, years 11.2 ± 3.4 11.8 ± 3.6 11.2 ± 3.5 10.7 ± 3.3
MMSE score 25.9 ± 3.1 28.4 ± 1.7 26.7 ± 2.5 23.5 ± 2.7
CDR score 0.6 ± 0.3 0.3 ± 0.2 0.6 ± 0.3 0.8 ± 0.3
GDS-15 score 3.3 ± 2.8) 3.4 ± 2.5 3.2 ± 2.6 3.3 ± 3.1
NPI score 14.5 ± 14.0 12.5 ± 12.1 12.7 ± 14.0 17.8 ± 14.7
DAD score 86.2 ± 15.9 93.4 ± 9.6 89.9 ± 13.1 76.7 ± 17.9
AD§, no. (%) 102 (46.2) 2 (3.8) 43 (47.8) 57 (72.2)
Declined§, n (%) 128 (57.9) 5 (9.6) 53 (58.9) 70 (88.6)
§according to the consensus diagnosis. Data are mean ± SD or number (%). SCI, subjective cognitive impairment;
MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating scale;
GDS, Geriatric Depression Scale; NPI, Neuropsychiatric Inventory; DAD, Disability Assessment for Dementia;
AD, Alzheimer’s disease.
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Table 2
Accuracy measures of clinic only and clinic + NPA classifications of etiology and disease course compared to consensus etiology and
consensus disease course
Reference consensus Stage TP FP TN FN Sensitivity Specificity PPV NPV Correctly classified Mean certainty
Etiology (AD y/n) Clinic only 71 21 98 31 69.6% 82.4% 77.2% 76.0% 76.5% 57.7%
Clinic + NPA 80 20 99 22 78.4% 83.2% 80.0% 81.8% 81.0%∗ 64.5%∗∗
Disease course Clinic only 109 37 56 19 85.2% 60.2% 74.7% 74.7% 74.7% 62.8%
(decline y/n) Clinic + NPA 114 40 53 14 89.1% 57.0% 74.0% 79.1% 75.6% 68.5%∗∗
∗p < 0.01. ∗∗p < 0.001. TP, true positives; FP, false positives; TN, true negatives; FN, false negatives; PPV, positive predictive value; NPV,
negative predictive value; AD, Alzheimer’s disease; NPA, neuropsychological assessment.
Table 3
Reclassification of syndrome at clinic only and clinic + NPA stages compared to the consensus syndrome
for patients classified as SCI, MCI, or dementia
Stage
Clinic only∗ Clinic + NPA∗ Consensus Number of
syndrome patients (%#)
SCI 28 (62.2)
SCI (n = 30) MCI 2 (4.4)
SCI (n = 45) Dementia 0 (0.0)
SCI 1 (2.2)
MCI (n = 15) MCI 14 (31.1)
Dementia 0 (0.0)
SCI 16 (14.7)
SCI (n = 18) MCI 2 (1.8)
Dementia 0 (0.0)
SCI 3 (5.8)
MCI (n = 78) MCI 62 (56.8)
MCI (n = 109) Dementia 13 (11.9)
SCI 0 (0.0)
Dementia (n = 10) MCI 1 (0.9)
Dementia 9 (8.3)
SCI 2 (1.8)
Indeterminate (n = 3) MCI 1 (0.9)
Dementia 0 (0.0)
SCI 0 (0.0)
MCI (n = 1) MCI 1 (1.6)
Dementia (n = 61) Dementia 0 (0.0)
SCI 0 (0.0)
Dementia (n = 60) MCI 3 (9.8)
Dementia 57 (93.4)
SCI 2 (33.3)
SCI (n = 2) MCI 0 (0.0)
Dementia 0 (0.0)
SCI 0 (0.0)
Indeterminate (n = 6) MCI (n = 3) MCI 3 (50.0)
Dementia 0 (0.0)
SCI 0 (0.0)
Indeterminate (n = 1) MCI 1 (16.7)
Dementia 0 (0.0)
∗Majority rating. Supplementary Figure 2 shows the distribution of majority (2/3 or 3/3) and indeterminate syn-
drome diagnosis ratings. # % of Clinic only. NPA, neuropsychological assessment; SCI, subjective cognitive
impairment; MCI, mild cognitive impairment.
the consensus syndrome in 90.9% (n = 40). In cases
initially assigned as SCI, 33.3% (n = 15) were reclas-
sified to MCI of which correctly in 93.3% (n = 14).
Of the patients who were initially diagnosed with the
MCI syndrome, 25.7% (n = 28) were reclassified to
SCI or dementia, for whom the reclassification was
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Table 4
Measures of reclassification in etiology and disease course from clinic only to clinic + NPA diagnosis
Reference Syndrome at clinic Reclassified Of which NRI NRI NRI
consensus only diagnosis after NPA correctly events non-events
Etiology (AD y/n) All (n = 221)# 32 (14.5%) 21 (65.6%) 8.8%∗ 0.8% 0.10∗
SCI (n = 45) 10 (22.2%) 6 (60.0%) 66.7%∗ –5.1% 0.61∗
MCI (n = 109) 13 (11.9%) 11 (84.6%) 9.6%∗ 7.0% 0.17∗
Dementia (n = 61) 7 (11.4%) 3 (42.9%) 0.0% –5.3% –0.05
Disease course (decline y/n) All (n = 221)# 34 (15.4%) 18 (52.9%) 3.9% –3.2% 0.01
SCI (n = 45) 10 (22.2%) 3 (30.0%) 28.6% –15.8%∗ 0.13
MCI (n = 109) 18 (16.5%) 13 (72.2%) 7.9%∗ 6.5% 0.14∗
Dementia (n = 61) 3 (4.9%) 0 (0.0%) –5.6%∗ 0.0% –0.06∗
∗p < 0.05. #Total number includes 6 indeterminate cases in which no majority syndrome could be assigned. NPA, neuropsychological
assessment; NRI, net reclassification improvement; AD, Alzheimer’s disease; SCI, subjective cognitive impairment; MCI, mild cognitive
impairment.
correct in 89.3% (n = 25). Only 1 case with initial
dementia was reclassified to MCI, which matched the
consensus syndrome.
Etiology was reclassified by the clinical experts in
the clinic + NPA diagnosis in 14.5% (n = 32), which
were correct when compared to the consensus etiol-
ogy in 65.6% (n = 21, Table 4). Overall, there was
net improvement in diagnosing etiology (NRI = 0.10,
z = 1.85, p = 0.032) after NPA and this was mainly
caused by an improvement of 8.8% in reclassifying
the etiology of AD cases from ‘no AD’ to ‘AD’.
The disease course prognosis was reclassified in
15.4% (n = 34) of patients, of which correctly accord-
ing to the consensus prognosis in 52.9% (n = 18).
The overall NRI for predicted disease course was
0.01 (z = 0.12, p > 0.05) indicating no significant
improvement.
To evaluate the added value of NPA across dif-
ferent syndromes, we examined reclassification from
clinic only to clinic + NPA diagnosis according to
the clinic only diagnosis of syndrome. Etiology was
more often correctly than incorrectly reclassified
in patients with an initial SCI or MCI syndrome,
but not dementia. NRIs were different per diagnos-
tic group and significant for the etiology diagnosis
in patients with initial SCI (NRI = 0.61, z = 1.81,
p = 0.036) and MCI (NRI = 0.17, z = 2.50, p = 0.006),
and for the disease course prognosis in patients with
initial MCI (NRI = 0.14, z = 1.68, p = 0.047). These
improvements were all driven by the NRI events,
indicating that the NPA is beneficial for ruling in
AD etiology. For the disease course prognosis, there
were more correct than incorrect reclassifications in
patients with initial MCI, but not SCI and demen-
tia. In initial dementia patients, a net worsening of
classification (NRI = –0.06, z = –1.73, p = 0.042) due
to the NPA was found in making a disease course
prognosis.
Indicators of correct reclassification
Characteristics of participants in whom syndrome,
etiology, or predicted disease course were cor-
rectly reclassified or correctly not reclassified (i.e.,
unchanged correct classification) after NPA are dis-
played in Supplementary Table 1. Higher MMSE
(27.5 versus 25.6, t = –3.5, p = 0.001) and lower
CDR scores (0.5 versus 0.6, t = 3.4, p = 0.001) were
found to be indicative of correct syndrome reclas-
sification. Correct reclassification of etiology was
characterized by worse AVLT delayed recall z-score
(–2.2 versus –1.5, t = 2.1, p = 0.039) and better per-
formance on digit span (15.7 versus 13.1, t = –2.5,
p = 0.012). Further, lower CDR scores (0.4 versus
0.6, t = –2.6, p = 0.010) and higher AVLT immediate
recall z-scores (–0.7 versus –1.5, t = –2.6, p = 0.011)
were indicators of correct reclassification of predicted
disease course. Figure 2 depicts the distribution of
correct and incorrect reclassifications for values of
the neuropsychological tests and scales that were
related to correct reclassification and Supplementary
Figure 1 further specifies the direction of these reclas-
sifications. Patients in whom the NPA did not change
an initially correct classification were in general char-
acterized by worse performance on both clinical
rating scales and neuropsychological tests. Patients’
age, years of education, score on a depression or dis-
ability questionnaire, and other neuropsychological
test results were not indicative of correct reclassifica-
tion or correct no reclassification.
DISCUSSION
In this study, we assessed the added value of NPA to
standard clinical evaluation in the diagnostic process
in memory clinic patients. NPA changed the diagno-
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Fig. 2. Percentages correctly and incorrectly reclassified from clinic only to clinic + NPA diagnosis. MMSE, Mini-Mental State Examination;
AVLT, Auditory Verbal Learning Task; CDR, Clinical Dementia Rating scale.
sis of the cognitive syndrome in 22% of patients and
the underlying etiology as well as the disease course
prognosis in 15%. Overall, this led to an increase in
correctly classified cases that could be attributed to
the NPA of about 18% for the cognitive syndrome, 5%
for the underlying etiology, and 1% for the predicted
disease course. Results demonstrated that the diag-
nostic and prognostic value of NPA when added to
the clinical evaluation depended on which initial syn-
drome was diagnosed. The NPA shows added value
for diagnosing syndrome and etiology in patients with
initial SCI or MCI, and for predicting disease course
in patients with an initial MCI syndrome. There was
no added diagnostic or prognostic value of the NPA
in patients suspected of dementia after the initial clin-
ical evaluation. Further, inclusion of the NPA in the
diagnostic process increased confidence in the diag-
nosis.
NPA had high added value in diagnosing the cog-
nitive syndrome, which is in line with the general
idea that neuropsychological tests are accurate in
determining the severity of cognitive deficits [32].
The value of NPA in diagnosing syndrome did not
depend on initial under- or overestimation of cogni-
tive complaints. There was added value of NPA in
diagnosing etiology in patients with an initial SCI or
MCI syndrome, and for predicting disease course in
patients with initial MCI. Our overall NRI was mainly
directed by the events NRI in these patients, indicat-
ing that the NPA supported the detection of persons
who had AD or declined at follow-up. In patients ini-
tially suspected of a dementia syndrome, the added
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value of the NPA was limited, and in some cases the
NPA even misled the experts into believing patients
would remain stable. Furthermore, incorrect reclas-
sifications of predicted disease course often occurred
in patients with SCI in whom it is likely to take more
than two years before a disease is clinically expressed
[33]. When determining whether or not to conduct a
NPA or to reclassify after the NPA has been con-
ducted, tests displayed in Fig. 2 and Supplementary
Figure 1 can be used as guideline in decision-making.
Results also showed that age and education, depres-
sion and disability scores were unrelated to the impact
of reclassification after NPA on the diagnosis. This
indicates that the added value of NPA in the diagnos-
tic process of memory clinic patients is not dependent
on these factors.
To our knowledge, no earlier study investigated the
added value of a complete NPA to the standard clin-
ical evaluation or examined neuropsychological test
results in a memory clinic setting by verifying diag-
noses through a reference diagnosis such that correct
reclassifications could be determined. Other stud-
ies concerning dementia diagnostics found changes
caused by the NPA of 11% for the etiology diagnosis
[34], 25% for diagnosing a combination of syndrome
and etiology [35], and 26% for diagnosing a combi-
nation of syndrome and etiology when both NPA and
MRI were added to the standard clinical assessment
[36]. However, divergent study populations and clas-
sification categories prevented reliable comparison
with our study.
This study simulated clinical decision-making
using comprehensive case descriptions and panel
discussions. This combination of individual and ple-
nary approaches has been found to produce very
similar results to a full plenary approach as often
adopted in clinical practice [37]. Additionally, assign-
ing diagnoses after each step allowed us to compare
classifications but also to investigate reclassifications,
which are important to consider when the goal is
to gain insight in the added value of a diagnostic
instrument. The NRI measure is implicitly weighted
by the event rate [38], which is useful when cer-
tain outcomes are not as prevalent as others, as is
the case in this study. Another strength of this study
is that diagnoses were compared against a refer-
ence standard to assess correctness. It should be
noted that clinical applications of the NPA other
than diagnostics, such as psycho-education, cog-
nitive training and treatment, were not assessed
here while these are also important utilities of
NPA [39].
A limitation of the study design is that incorpo-
ration bias may have occurred since the index test
results were also part of the reference standard, as
is often inevitable in dementia diagnostic studies
[40]. This may have led to an overestimation of
the various measures of diagnostic accuracy. Also,
there was a maximum follow-up of only two years.
There might have been an overestimation of expected
decline in dementia patients while the period is too
short to decline for persons with SCI. Most patients
were followed for two years but some patients only
received a one-year follow-up assessment, which
slightly affected the diagnostic accuracy measures.
Further, although amyloid and tau biomarkers are
more often used in clinical practice, we did not incor-
porate this information in the diagnostic process nor
did we verify the etiology reference standard based
on biomarker information. Moreover, the expert pan-
els already diagnosed etiology and predicted disease
course correctly in about 75% based on the clinical
evaluation only. This high rate is likely explained by
the extensive information made available in the clin-
ical evaluation leaving less room for improvement
for NPA and by the extensive diagnostic experience
of our clinical experts. Additionally, this study was
performed in specialized centers and results may
therefore not be generalizable to other settings. Use
of multidisciplinary teams including a neuropsychol-
ogist who interprets and transfers NPA findings in a
comprehensive manner during the diagnostic process
may overcome this limitation in less specialized cen-
ters. The added value of NPA may also depend on
the choice of NPA tests or the order of presentation
of additional test results, and may prove differently
when more sensitive or specific measures would be
used or when NPA and MRI would be presented in
a different order. Lastly, our simulation was a sim-
plification of actual practice because we presented
summarized NPA results, which possibly led to an
underestimation of the impact of the NPA since a
neuropsychologist would also provide a contextual
interpretation of the results, and take part in multidis-
ciplinary meetings in clinical practice.
Although the NPA is widely applied in patients
presenting with cognitive complaints, the diagnostic
and prognostic value was not evaluated before in a
large prospective study simulating clinical practice.
We conclude that the added value of the NPA depends
on the initial clinical impression of syndrome, and is
different for diagnosing syndrome, etiology or pre-
dicting disease course. This may stimulate a more
individualized approach in the diagnostic evaluation
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of persons with cognitive complaints, which may ben-
efit cost-effectiveness of NPA. To make an optimal
diagnosis and prognosis, we recommend the use of
NPA as decisive investigation in patients who are
considered non-demented at initial clinical evalua-
tion and in patients in whom more certainty about the
diagnosis is desired. In patients suspected of demen-
tia, the diagnostic value of the NPA is limited and
this should lead to reconsideration of administering
NPA bearing in mind alternative purposes of NPA
such as inventorying profiles of cognitive strengths
and weaknesses, burden and care needs.
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